Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
| ▸ | PCNA | P12004 | 1/20 | 0.30 |
| ▸ | TACR3 | P29371 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8373498 | 0.95 | LMNA (0.66) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL10875551 | 0.93 | LMNA (0.63) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL619948 | 0.90 | LMNA (0.60) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL8978033 | 0.89 | LMNA (0.58) | LMNASMN1; SMN2 | |
| SCHEMBL9189587 | 0.89 | LMNA (0.61) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL17264622 | 0.86 | LMNA (0.83) | LMNASMN1; SMN2CYP2C19HIF1AMAP2K1 | |
| SCHEMBL15760478 | 0.84 | LMNA (0.67) | LMNASMN1; SMN2CYP2C19HIF1AMAP2K1 | |
| Iopamidol SCHEMBL471484 | 0.83 | LMNA (1.00) | LMNASMN1; SMN2CYP2C19HIF1A | |
| Iopamidol SCHEMBL7101453 | 0.83 | LMNA (1.00) | LMNASMN1; SMN2CYP2C19HIF1A | |
| Iopamidol SCHEMBL27781 | 0.83 | LMNA (1.00) | LMNASMN1; SMN2CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3300499-B1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE PREPARATION OF NON-IONIC CONTRAST AGENTS | HOVIONE SCIENTIA LTD (IE) | 2023-10-04 | — | — | EP | disclosed |
| CN-116730858-A | Method for preparing intermediate for preparing non-ionic contrast agent | 好利安科技有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11059021-B2 | Process for the preparation of intermediates useful in the preparation of non-ionic contrast agents | HOVIONE SCIENTIA LIMITED (IE) | 2021-07-13 | — | — | US | disclosed |
| US-20180169607-A1 | Process for the Preparation of Intermediates Useful in the Preparation of Non-ionic Contrast Agents | HOVIONE SCIENTIA LIMITED (IE) | 2018-06-21 | — | — | US | disclosed |
| EP-3300499-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE PREPARATION OF NON-IONIC CONTRAST AGENTS | Hovione Scientia Limited (IE) | 2018-04-04 | — | — | EP | disclosed |
| WO-2016193740-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE PREPARATION OF NON-IONIC CONTRAST AGENTS | HOVIONE SCIENTIA LIMITED (IE) | 2016-12-08 | — | — | WO | disclosed |
| US-8835672-B2 | Manufacture of a triiodinated contrast agent | HOVIONE INTER LIMITED (CH) | 2014-09-16 | — | — | US | disclosed |
| US-8835672-B2 | Manufacture of a triiodinated contrast agent | HOVIONE INTER LIMITED (CH) | 2014-09-16 | — | — | US | disclosed |
| US-20140155648-A1 | Manufacture of a Triiodinated Contrast Agent | HOVIONE INTER LIMITED (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20140155648-A1 | Manufacture of a Triiodinated Contrast Agent | HOVIONE INTER LIMITED (CH) | 2014-06-05 | — | — | US | disclosed |
| EP-0707572-A1 | IODINATED OLIGOMERIC COMPOUNDS AND DIAGNOSTIC COMPOSITIONS CONTAINING THE SAME | BRACCO S.p.A. (IT) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001966-A1 | IODINATED OLIGOMERIC COMPOUNDS AND DIAGNOSTIC COMPOSITIONS CONTAINING THE SAME | BRACCO S.P.A. (IT) | 1995-01-19 | — | — | WO | disclosed |
| US-5349085-A | IODIXANOL; 1,3-bis(acetylamino)-N,N'-bis(3,5-bis(2,3dihydroxypropylaminocarbonyl)-2,4,6-triiodophenyl)-2-hydroxypropane | NYCOMED IMAGING AS (NO) | 1994-09-20 | — | — | US | disclosed |
| US-5204086-A | 2,4,6-triiodoisophthalamide derivatives | NYCOMED IMAGING AS (NO) | 1993-04-20 | — | — | US | disclosed |
| EP-0108638-B1 | X-RAY CONTRAST AGENTS | NYEGAARD & CO. A/S (NO) | 1986-07-16 | — | — | EP | disclosed |
| EP-0105752-B1 | X-RAY CONTRAST AGENTS | NYEGAARD & CO. A/S (NO) | 1986-05-07 | — | — | EP | disclosed |
| EP-0108638-A1 | X-ray contrast agents | NYEGAARD & CO. A/S (NO) | 1984-05-16 | — | — | EP | disclosed |
| EP-0105752-A1 | X-ray contrast agents | NYEGAARD & CO. A/S (NO) | 1984-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059021-B2 | Process for the preparation of intermediates useful in the preparation of non-ionic contrast agents | PPIP5K2, IPO4, ITPA | LMNA 651/4885SMN1; SMN2 3123/4885CYP2C19 2333/4885 |
| US-20140155648-A1 | Manufacture of a Triiodinated Contrast Agent | SAT1, LYPLA2, AGPAT5 | LMNA 2871/4885SMN1; SMN2 4778/4885CYP2C19 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.